Becton Dickinson & Co (BDX) · Nov 5, 2026 · Earnings

BD earnings beat, but FY27 guidance stays low-single-digit

Beat — Adj. EPS $4.15 vs ~$4.07 consensus; revenue $5.274B vs ~$5.11B

BD’s earnings beat consensus in Q4, while its first FY2027 guidance points to steady—not accelerating—growth after the Life Sciences spin-off.

BD enters this report as a newly focused MedTech company following the February 9, 2026 separation of its Life Sciences business, with management trying to prove that the remaining portfolio can produce durable growth and cash flow. The prior setup already pointed to low-single-digit revenue growth and roughly $13.25 of FY2027 adjusted EPS consensus, so the key question was execution—not whether BD would suddenly reaccelerate.

The quarter beat the market’s operating hurdle. Fourth-quarter revenue reached $5.274 billion, ahead of the published consensus near $5.11 billion, while adjusted EPS was $4.15 versus approximately $4.07 expected. The beat was broad rather than dependent on one segment: Medical Essentials grew 5.9%, BioPharma Systems 6.5%, and Interventional 7.6% on a reported basis, although Connected Care was much softer at 1.6%. (Financial Highlights) 〔0〕

MetricCurrentComparisonConsensus / guide
Q4 revenue (Financial Highlights)$5.274B$5.005B~$5.11B
Q4 adjusted diluted EPS (Financial Highlights)$4.15$3.26~$4.07
FY2026 adjusted diluted EPS (EPS reconciliation)$12.70$11.90$12.62–$12.72 prior guide
FY2026 free cash flow (Cash Flow reconciliation)$2.933B$2.058B
FY2027 adjusted diluted EPS (Guidance table)$13.10–$13.30$12.70~$13.25
FY2027 revenue growth (Guidance table)Low single-digit4.9% FY2026Low single-digit

The full-year quality improved, but the new outlook is not an acceleration signal. Continuing-operations adjusted EPS rose to $12.70, and free cash flow increased 42.5% to $2.933 billion, helped by stronger operating cash generation. But FY2027 guidance of $13.10–$13.30 centers around $13.20, essentially in line with the roughly $13.25 consensus, while revenue is again guided only to low-single-digit growth. That keeps the post-spin-off story intact rather than upgrading it.

The restructuring bill shows the transformation is still costing money. BD recorded $642 million of full-year restructuring costs, including $450 million of non-cash asset impairments tied to exiting activities that no longer fit its strategy. The improved adjusted results and cash flow matter more than the accounting charge for this quarter, but the charge confirms that the “focused MedTech” model is still being reshaped rather than fully proven.

Bottom line: BD delivered a clean quarterly beat and stronger cash generation, but its first FY2027 outlook is broadly what the market already expected. This advances execution modestly; it does not yet rewrite the company’s growth story.

What to watch next

Fiscal Q1 2027 results, early February 2027

Original filing on SEC EDGAR

More Becton Dickinson & Co news

BD earnings beat, but FY27 guidance stays low-single-digit | BDX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.